Tarsus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Tarsus Pharmaceuticals generated cash of -$117,493,000, which is less than the previous year. Cash used in financing activities reached the amount of $130,175,999 last year. Net change in cash is therefore $153,287,000.
Cash Flow
| 2018 | -1.18M | -7K | 3.56M |
|---|---|---|---|
| 2019 | -3.67M | -175K | 59.44M |
| 2020 | -21.13M | -456K | 131.77M |
| 2021 | 3.74M | -586K | 21K |
| 2022 | -49.03M | -144.62M | 93.98M |
| 2023 | -117.49M | 140.60M | 130.17M |
TARS Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 71.66M | 171.33M | 168.14M | 57.97M | 2.37M | 1K |
Operating activities | ||||||
Net income | -135.89M | -62.09M | -13.82M | -26.81M | -4.67M | -1.31M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 877K | 325K | 312K | 96K | 37K | 1K |
Stock-based compensation expense | 19.83M | 13.46M | 8.45M | 839K | 18K | 0 |
| Deferred income tax benefit | 19.83M | 13.46M | 8.45M | 839K | 18K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | -14.13M | -3.49M | -73K | 16K | -32K | 0 |
Inventories | -3.10M | 3.49M | 73K | -16K | 32K | 0 |
Accounts payable | 13.24M | 821K | 3.88M | 3.24M | 245K | 131K |
Cash generated by operating activities | -117.49M | -49.03M | 3.74M | -21.13M | -3.67M | -1.18M |
Investing activities | ||||||
Purchases Of Investments | -28.66M | -149.43M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.50M | -506K | -586K | -456K | -175K | -7K |
Acquisitions Net | 0 | 144.12M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 140.60M | -144.62M | -586K | -456K | -175K | -7K |
Financing activities | ||||||
Common Stock Issued | 118.59M | 74.35M | 5.49M | 91.67M | 57.45M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -28K | 0 | 0 |
Repayments of term debt | 10M | 20M | 0 | 0 | 1.98M | 0 |
Cash used in financing activities | 130.17M | 93.98M | 21K | 131.77M | 59.44M | 3.56M |
Net Change In Cash | 153.28M | -99.67M | 3.18M | 110.17M | 55.59M | 2.37M |
Cash at end of period | 224.94M | 71.66M | 171.33M | 168.14M | 57.97M | 2.37M |
| Data source | Data source | Data source | Data source |